Table 1.
Demographics, RVA vaccination, and the clinical score of Lebanese breakthrough cases included in this study.
| Specimen ID | Gender | Date of admission (MM/YYYY) | Age (y) | Vaccine | No. of doses | Days to infection since last dose | Vesikari score |
|---|---|---|---|---|---|---|---|
| LBN/A004/G1P[8] | M | 02/2011 | 3.15 | RV1 | 1 | 1086 | 14 |
| LBN/H006/G1P[8] | F | 05/2011 | 2.19 | RV1 | 1 | ND3 | 12 |
| LBN/N222/G1P[8] | M | 12/2011 | 0.68 | RV1 | 1 | 30 | 13 |
| LBN/H151/G1P[8] | M | 12/2011 | 1.38 | RV1 | 2 | 260 | 16 |
| LBN/M154/G1P[8] | M | 07/2011 | 3.87 | RV5 | 3 | ND | 16 |
| LBN/N280/G1P[8] | F | 01/2012 | 0.42 | RV1 | 1 | 73 | 18 |
| LBN/N318/G1P[8] | F | 05/2012 | 0.91 | RV1 | 1 | 171 | 16 |
| LBN/A170/G1P[8] | F | 02/2013 | 1.69 | RV1 | 2 | 513 | 11 |
| LBN/A081/G2P[4] | F | 11/2011 | 2.45 | RV1 | 2 | 773 | 16 |
| LBN/A082/G2P[8] | M | 11/2011 | 2.18 | RV1 | 2 | 417 | 12 |
| LBN/A094/G2P[4] | F | 12/2011 | 0.45 | RV1 | 1 | 65 | 13 |
| LBN/H159/G2P[4] | F | 03/2012 | 2.73 | RV5 | 3 | ND | 19 |
| LBN/NG034/G2P[4] | F | 01/2012 | 1.62 | RV1 | 2 | 174 | 11 |
| LBN/H178/G2P[4] | F | 04/2012 | 0.71 | RV1 | 1 | ND | 12 |
| LBN/H195/G2P[4] | M | 07/2012 | 0.56 | RV1 | 1 | ND | 15 |
| LBN/H198/G2P[4] | F | 12/2012 | 1.8 | RV1 | 1 | ND | 15 |
| LBN/NG144/G2P[4] | M | 11/2012 | 0.81 | RV1 | 2 | 170 | 16 |
| LBN/H237/G2P[4] | M | 12/2012 | 1.47 | RV1 | 2 | 524 | 15 |
| LBN/H239/G2P[4] | M | 12/2012 | 1.02 | RV1 | 2 | 106 | 16 |
| LBN/H248/G2P[4] | M | 06/2013 | 2.99 | ND1 | ND2 | ND | 12 |
| LBN/NG168/G2P[4] | M | 01/2013 | 1.46 | RV1 | 2 | 423 | 9 |
| LBN/NG169/G2P[4] | F | 01/2013 | 0.96 | RV1 | 2 | 229 | 10 |
| LBN/NG189/G2P[4] | F | 02/2013 | 3.37 | RV1 | 2 | 1185 | 12 |
| LBN/NG198/G2P[4] | M | 02/2013 | 0.9 | RV1 | 2 | 263 | 11 |
| LBN/M078/G4P[8] | M | 05/2011 | 0.26 | RV5 | 1 | ND | 11 |
| LBN/NG064/G4P[8] | M | 03/2012 | 0.79 | RV1 | 2 | 344 | 15 |
| LBN/NG068/G4P[8] | F | 03/2012 | 1.23 | RV1 | 2 | 295 | 13 |
| LBN/R077/G4P[8] | F | 04/2012 | 2.16 | RV5 | 3 | 634 | 14 |
| LBN/H250/G4P[8] | F | 10/2013 | 1.75 | RV5 | 1 | ND | 12 |
| LBN/NG160/G4P[8] | M | 01/2013 | 0.42 | RV1 | 2 | 28 | 9 |
| LBN/A164/G4P[8] | M | 02/2013 | 1.17 | RV1 | 2 | 342 | 12 |
| LBN/M006/G9P[8] | F | 08/2011 | 1.57 | RV1 | 1 | 328 | 19 |
| LBN/N486/G9P[8] | F | 12/2012 | 4.24 | RV1 | 2 | 1058 | 18 |
| LBN/N488/G9P[8] | F | 12/2012 | 0.95 | RV1 | 2 | 49 | 11 |
| LBN/A014/G9P[8] | M | 03/2011 | 2.1 | RV1 | 2 | 658 | 16 |
| LBN/N394/G9P[8] | M | 08/2012 | 0.9 | RV1 | 2 | 140 | 17 |
| LBN/M036/G9P[8] | F | 03/2011 | 1.02 | RV5 | 3 | ND | 18 |
| LBN/N087/G9P[8] | F | 08/2011 | 2.59 | RV1 | 2 | 427 | 12 |
| LBN/NG142/G9P[8] | F | 11/2012 | 0.47 | RV1 | 2 | 109 | 9 |
| LBN/NG164/G9P[8] | M | 01/2013 | 1.04 | RV1 | 2 | 106 | 13 |
| LBN/M199/G9P[8] | F | 03/2013 | 0.24 | RV1 | 1 | 26 | 15 |
| LBN/NG203/G9P[8] | F | 03/2013 | 0.25 | RV1 | 2 | 31 | 11 |
| LBN/H017/G9P[4] | M | 01/2011 | 0.55 | RV5 | 1 | 301 | 18 |
1
ND, not-determined; clinical records reveals that the subject received RVA vaccination, however, unnoted whether it was a Rotarix® or a RotaTeq®.
2
Number of doses of administered RVA vaccination was not determined in clinical records.
3
Days to infection since last dose was undetermined; however, it is confirmed that latest RVA vaccination dose was administered at least >1 month prior to infection.